scholarly journals Second primary cancers and recurrence in patients after resection of colorectal cancer: An integrated analysis of trials by Japan Clinical Oncology Group: JCOG1702A

2020 ◽  
Author(s):  
Kiyo Tanaka ◽  
Gakuto Ogawa ◽  
Junki Mizusawa ◽  
Tomohiro Kadota ◽  
Kenichi Nakamura ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
General Population ◽  
Cumulative Incidence ◽  
National Database ◽  
Integrated Analysis ◽  
Second Primary ◽  
Primary Cancer ◽  
Second Primary Cancer ◽  
Surveillance Strategy ◽  
Second Primary Cancers

Abstract Background Improvements in early detection and treatment have resulted in an increasing number of long-term survivors of colorectal cancer (CRC). For the survivors, second primary cancer and recurrence are important issues; however, evidence for an appropriate surveillance strategy remains limited. This study aimed to investigate the frequency and timing of second primary cancer in patients after surgery for exploring an appropriate surveillance strategy by using an integrated analysis of three large-scale randomized controlled trials in Japan. Methods The eligibility criteria of three trials included histologically confirmed CRC and having received surgery. The timing, site and frequency of second primary cancers and recurrence were investigated. Risk factors associated with second primary cancers were also examined. The standardized incidence ratio (SIR) of second primary cancers compared with the national database of the Japan Cancer Registry was estimated. Results A total of 2824 patients were included in this study. The cumulative incidence of second primary cancer increased over time. The SIR of any second primary cancer was 1.07 (95% CI: 0.94–1.21). The SIR for second primary cancers of colon was 1.09 (95% CI: 0.79–1.47). The cumulative incidence of recurrence almost reached plateau at 3 years. Conclusions A common surveillance strategy for the general population can be applied even for curatively resected CRC patients, as the risk of second primary cancers was almost the same as that of the general population.

Second primary cancers and recurrence in patients after resection of colorectal cancer: An integrated analysis of trials by Japan Clinical Oncology Group: JCOG0205, JCOG0212, JCOG0404 (JCOG1702A).

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 561-561
Author(s):  
Kiyo Tanaka ◽  
Gakuto Ogawa ◽  
Junki Mizusawa ◽  
Junko Eba ◽  
Hiroshi Katayama ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Risk Factors ◽  
Cumulative Incidence ◽  
Second Primary ◽  
Primary Cancer ◽  
Second Primary Cancer ◽  
Surveillance Strategy ◽  
Second Primary Cancers ◽  
Over Time

561 Background: Improvements in early detection and treatment have resulted in an increasing number of long-term survivors of colorectal cancer (CRC). For the survivors, Second primary cancers and recurrence are important issues, but the evidence for appropriate surveillance strategy is limited. The aim of this study was to investigate the frequency and the timing of second primary cancers and recurrence in patients (pts) after surgery using 3 randomized trials (J0205, J0212 and J0404) conducted by Colorectal Cancer Study Group of JCOG. Methods: Eligibility criteria included histologically proven CRC and having received surgery. The timing, site and frequency of second primary cancer and recurrence were investigated. Risk factors associated with the events were explored. Standardized incidence ratio (SIR) about second primary cancer compared with national database of Japan Cancer Registry was estimated. Results: A total of 2,824 pts with a median follow-up time of 6 years were included. Median age was 62 years old (23-75), male/female was 58%/42%, and stage 0/I/II/III/IV was 0.2%/8.7%/25.4%/64.8%/0.9%. Pts with 5-FU based adjuvant chemotherapy were 63%. Cumulative incidence of second primary cancer increased constantly over time (Table). Among 240 pts, the most common site was lung (37), stomach (35) and colon (32). In multivariable analysis, age (over 64 years old) and sex (male) were risk factors (age HR: 1.60 (95% CI: 1.24-2.07), sex HR: 1.36 (95% CI: 1.04-1.78)). The SIR of any second primary cancers was 1.07 (95% CI: 0.94-1.21). The SIR for second primary cancers of colon was 1.09 (95% CI: 0.79-1.47). On the other hand, cumulative incidence of recurrence almost reached at 3 years. Conclusions: Common surveillance strategy can be applied even for curatively resected CRC pts after 3 years from surgery, because the risk of second primary cancer was almost same as general population over time. The necessity of intensive follow-up to detect recurrence decreases after 3 years. [Table: see text]

Development of second primary cancers in breast cancer survivors.

2016 ◽  
Vol 34 (3_suppl) ◽  
pp. 257-257
Author(s):  
Hong Kyu Jung ◽  
Jihyoun Lee ◽  
Zisun Kim ◽  
Min Hyuk Lee ◽  
Ilkyun Lee
Keyword(s):  
Breast Cancer ◽  
Endometrial Cancer ◽  
Thyroid Cancer ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Second Primary ◽  
Primary Cancer ◽  
Second Primary Cancer ◽  
Breast Cancer Patients ◽  
Second Primary Cancers

257 Background: Breast cancer survivors have slightly increased risk of second primary cancers. Importance of screening for second cancers has been raised due to increased survival in those populations. Not only having genetic risk such as BRCA mutation, but also treatment-related risk presents. The most common second primary cancer is breast cancer. Colon cancer, uterine cancer, and ovarian cancer showed increased cumulative incidence. In this study, we assessed development second primary cancers in breast cancer survivors. Methods: Medical record of breast cancer patients was reviewed retrospectively in three tertiary medical institutions. Available data of ICD-9 record after breast cancer diagnosis was evaluated. Diagnosis of second primary breast cancer was excluded in evaluation. Results: Since Jan 1989 to Jan 2014, available medical records were reviewed in breast cancer patients(N = 5880) in three institutions(one urban and the other two rural institutions). Cumulative incidence of overall second primary cancers was 4.57%. Among 269 second primary cancers, thyroid cancer(44.2%) was most common second primary cancer, followed by gastric cancer(10.0%). Gastric cancers were more common in rural institution than urban area(14.2 % vs 5.5%), while incidence of thyroid cancer is elevated in urban institution(57.8% vs 31.9%). Among 9 patients who has been diagnosed endometrial cancer, 7 patients had history of selective estrogen receptor modulator(tamoxifen or toremifen) treatment. Development of lung cancer was not related to breast cancer radiation treatment(4 of 15 patients). Leukemia after breast cancer treatment was diagnosed in 5 patients (8.5% of second primary cancers), three of them were adult T cell leukemia and two of them were acute myeloid leukemia. Conclusions: Incidence of cancer in general population was reflected to development of second primary cancer in breast cancer survivors. Endocrine treatment was related increased incidence of endometrial cancer, respectively. Application of personalized cancer screening plan would be important in this patient group.

Second Primary Cancer in Patients with Colorectal Cancer after a Curative Resection

2009 ◽  
Vol 26 (5) ◽  
pp. 400-405 ◽  
Author(s):  
Shingo Noura ◽  
Masayuki Ohue ◽  
Yosuke Seki ◽  
Koji Tanaka ◽  
Masaaki Motoori ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Curative Resection ◽  
Second Primary ◽  
Primary Cancer ◽  
Second Primary Cancer

scholarly journals Second Primary Cancers After Gastric Cancer, and Gastric Cancer as Second Primary Cancer

2021 ◽  
Vol Volume 13 ◽  
pp. 515-525
Author(s):  
Guoqiao Zheng ◽  
Kristina Sundquist ◽  
Jan Sundquist ◽  
Tianhui Chen ◽  
Asta Försti ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Second Primary ◽  
Primary Cancer ◽  
Second Primary Cancer ◽  
Second Primary Cancers

scholarly journals Machine Learning in Prediction of Second Primary Cancer and Recurrence in Colorectal Cancer

2020 ◽  
Vol 17 (3) ◽  
pp. 280-291
Author(s):  
Wen-Chien Ting ◽  
Yen-Chiao Angel Lu ◽  
Wei-Chi Ho ◽  
Chalong Cheewakriangkrai ◽  
Horng-Rong Chang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Machine Learning ◽  
Second Primary ◽  
Primary Cancer ◽  
Second Primary Cancer

The incidence of second primary cancer in male and female patients with initial colorectal cancer

2022 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Yanyan Chen ◽  
Chao Han ◽  
Yadi Huang ◽  
Chao Liu ◽  
Siqi Sheng ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Second Primary ◽  
Primary Cancer ◽  
Second Primary Cancer ◽  
Male And Female ◽  
Female Patients

Second primary cancers in patients with sporadic deficient mismatch repair (dMMR) colorectal cancer (CRC).

2021 ◽  
Vol 39 (3_suppl) ◽  
pp. 45-45
Author(s):  
Ayman Alidina ◽  
Lara Rachel Lipton ◽  
Lucy Gately ◽  
Iain Skinner ◽  
Shehara Ramyalini Mendis ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Early Stage ◽  
Elevated Risk ◽  
Stage I ◽  
Braf V600e ◽  
Second Primary ◽  
Primary Cancer ◽  
Colonoscopic Surveillance ◽  
Second Primary Cancers ◽  
Deficient Mismatch Repair

45 Background: Patients with hereditary non polyposis colorectal cancer (HNPCC) diagnosed with CRC have an elevated risk of a second primary CRC (SPCRC) and of rapid primary cancer development. This informs both initial surgical approach and endoscopic surveillance intervals. A feature of HNPCC is dMMR, also found in 15% of sporadic CRC, where the risk of SPCRC has yet to be defined. Methods: We examined a multi-site comprehensive CRC database (Melbourne, Australia), where prospectively collected data includes family history (including HNPCC), histology, surgery performed and incidence of second primary cancer. Sporadic dMMR included any case with a BRAF V600E mutation, confirmed hypermethylation, negative germline testing, or age over 60 years. We explored the incidence and timing of SPCRC in patients with early stage sporadic dMMR (or MSI-H) versus pMMR cancers. Results: From February 2004 to December 2019, 7442 patients diagnosed with stage I-III CRC were recorded. MMR status was known in 4079 (54.8%), including 714 with dMMR colorectal cancer (17.4%) of which 575 (14.6%) were deemed sporadic dMMR. Sporadic dMMR patients were older (mean 76.2 years vs 65.9 years, p = < 0.001), more likely to be female (65.2% vs 42%, p = < 0.001) and have a right sided primary (80.9% vs 32.8%, p = < 0.001), compared to patients with pMMR CRC. A SPCRC was diagnosed in 11/575 patients (1.91%) with sporadic dMMR CRC versus 27/3365 (0.83%) patients with pMMR CRC (HR = 2.57, 95% CI 1.28 - 5.17, p = 0.008). Median time to SPCRC was 1.13 years vs 2.38 years (p = 0.49). The SPCRC diagnosed in sporadic dMMR CRC vs pMMR CRC were more likely to be dMMR ((72.7%) vs (25.9%), p = 0.03), but a similar number were stage I or II ((81.8%) vs (81.5%)) and a similar number were surveillance detected ((72.7%) vs (77.8%). Conclusions: Patients with sporadic dMMR appear to have a significantly elevated risk of SPCRC compared to the pMMR population and were diagnosed at a shorter interval. The SPCRC is also more likely to also be dMMR. Increased colonoscopic surveillance of patients presenting with an initial sporadic dMMR cancer should be considered where clinically appropriate.

Prostate Brachytherapy and Second Primary Cancer Risk: A Competitive Risk Analysis

2011 ◽  
Vol 29 (34) ◽  
pp. 4510-4515 ◽  
Author(s):  
Karel A. Hinnen ◽  
Michael Schaapveld ◽  
Marco van Vulpen ◽  
Jan. J. Battermann ◽  
Henk van der Poel ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Rectal Cancer ◽  
General Population ◽  
Lead Time ◽  
Incidence Rates ◽  
Second Primary ◽  
Prostate Brachytherapy ◽  
Primary Cancer ◽  
Second Primary Cancer

Purpose To assess the risk of second primary cancer (SPC) after [125I]iodine prostate cancer brachytherapy compared with prostatectomy and the general population. Patients and Methods In a cohort consisting of 1,888 patients with prostate cancer who received monotherapy with brachytherapy (n = 1,187; 63%) or prostatectomy (n = 701; 37%), SPC incidences were retrieved by linkage with the Dutch Cancer Registry. Standardized incidence rates (SIRs) and absolute excess risks (AERs) were calculated for comparison. Results A total of 223 patients were diagnosed with SPC, 136 (11%) after brachytherapy and 87 (12%) after prostatectomy, with a median follow-up of 7.5 years. The SIR for all malignancies, bladder cancer, and rectal cancer were 0.94 (95% CI, 0.78 to 1.12), 1.69 (95% CI, 0.98 to 2.70), and 0.90 (95% CI, 0.41 to 1.72) for brachytherapy and 1.04 (95% CI, 0.83 to 2.28), 1.82 (95% CI, 0.87 to 3.35), and 1.50 (95% CI, 0.68 to 2.85) for prostatectomy, respectively. Bladder SPC risk was significantly increased after brachytherapy for patients age 60 years or younger (SIR, 5.84; 95% CI, 2.14 to 12.71; AER, 24.03) and in the first 4 years of follow-up (SIR, 2.14; 95% CI, 1.03 to 3.94; AER, 12.24). Adjusted for age, the hazard ratio (brachytherapy v prostatectomy) for all SPCs combined was 0.87 (95% CI, 0.64 to 1.18). Conclusion Overall, we found no difference in SPC incidence between patients with prostate cancer treated with prostatectomy or brachytherapy. Furthermore, no increased tumor incidence was found compared with the general population. We observed a higher than expected incidence of bladder SPC after brachytherapy in the first 4 years of follow-up, probably resulting from lead time or screening bias. Because of power limitations, a small increased SPC risk cannot be formally excluded.

scholarly journals Conventional Western Treatment Associated With Chinese Herbal Medicine Ameliorates the Incidence of Head and Neck Cancer Among Patients With Esophageal Cancer

2019 ◽  
Vol 18 ◽  
pp. 153473541983435
Author(s):  
Chia-Chen Chang ◽  
Kuo-Wei Bi ◽  
Hung-Jen Lin ◽  
Yuan-Chih Su ◽  
Wen-Ling Wang ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Herbal Medicine ◽  
Head And Neck ◽  
Chinese Herbal Medicine ◽  
Cumulative Incidence ◽  
Second Primary ◽  
Primary Cancer ◽  
Second Primary Cancer ◽  
Chinese Herbal ◽  
Kaplan Meier

Background: Because of advances in medical treatment, the survival of cancer patients is prolonged. In line with the prolonged survival time of cancer the incidence of second primary cancer has increased. There is currently no effective way to prevent the occurrence of secondary primary cancer (SPC). Objectives: The aim of this study is to evaluate whether Chinese Herbal Medicine (CHM) is correlated with reduced occurrence of second primary cancer (SPC) of head and neck (H&N) in patients with esophageal cancer (EC). Method: We identified 15,546 patients who were diagnosed with esophageal cancer between Jan 1, 2000, and Dec 31, 2010. The patients with H&N cancer before receiving CHM were excluded. After the selection and matching process, both CHM and non-CHM cohorts each contained 850 individuals. We compared the cumulative incidence of SPC of H&N with or without CHM treatment in patients with EC by the Kaplan-Meier method. NodeXL is used to run a network analysis of CHM to examine the association between herbs and formulas. Results: Compared with non-CHM users, CHM-users showed a reduced incidence rate of SPC of H&N among the patients with EC. Reduced cumulative incidence of SPC of H&N among patients with EC was noted in the CHM cohort compared to the non-CHM cohort. The most commonly used single herbs and formulas were associated with reducing SPC occurrence. Conclusion: We propose that CHM as an adjuvant therapy may prevent the occurrence of SPC of H&N in patients with EC.

Sign in / Sign up

Export Citation Format

Share Document